Here are four insights:
1. Researchers randomized 27 Crohn’s disease patients in remission to 2000 IU of vitamin D or placebo every day for three months.
2. The study found that at the end of three months, 25-hydroxyvitamin D concentrations were significantly higher in the active treatment group. They also showed stable maintenance of intestinal permeability.
3. On the other hand, the placebo group observed significant increases in both small bowel and gastro-duodenal permeability.
4. “While the study is exciting and may translate to improved treatment for CD, we also recognize that there is not yet sufficient evidence to recommend vitamin D as an adjunctive treatment and further randomized controlled trials are need,” senior author Maria O’Sullivan, PhD, of St. James’s Hospital in Dublin, Ireland, told Reuters Health. “Currently it seems sensible, that at a minimum, we aim to prevent vitamin D deficiency in people with this disease.”
More articles on GI/endoscopy:
Dr. Sheetal Sharma joins Mercy Clinic Gastroenterology
Skiff Medical Center’s endoscopy suite acquires FUJIFILM technology
GI physician leader to know: Dr. William Sandborn of UC San Diego School of Medicine
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.